Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alvaro Taus

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Epigenetics|December 9, 2014
Methylation status of IGFBP-3 as a useful clinical tool for deciding on a concomitant radiotherapyOlga Pernía, Cristobal Belda-Iniesta, Veronica Pulido, et al.
British Journal of Cancer|October 26, 2022
Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib studyAlejo Rodriguez-Vida, Pablo Maroto, Albert Font, et al.
ESMO Open|August 20, 2019
A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancerJuan-Miguel Cejalvo, Wolfgang Jacob, Tania Fleitas Kanonnikoff, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 14, 2014
Assessment of ALK status by FISH on 1000 Spanish non-small cell lung cancer patientsJoana Vidal, Sergi Clavé, Silvia de Muga, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2017
First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid TumorsManuel Hidalgo, Maria Martinez-Garcia, Christophe Le Tourneau, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 28, 2022
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R StudyNicolas Girard, Jair Bar, Pilar Garrido, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 28, 2023
Open-label phase II clinical trial of ketoconazole as CYP17 inhibitor in metastatic or advanced non-resectable granulosa cell ovarian tumors: the GREKO (GRanulosa Et KetOconazole) trial, GETHI 2011-03Jesus Garcia-Donas, Alicia Hurtado, Laia Garrigos, et al.
Frontiers in Oncology|November 16, 2020
A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable <i>KRAS</i> Mutation Who Failed Prior Platinum-Based Therapy: JUNIPERJonathan W Goldman, Julien Mazieres, Fabrice Barlesi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2015
First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid TumorsDidier Meulendijks, Wolfgang Jacob, Maria Martinez-Garcia, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 20, 2025
Clinical outcomes and subsequent therapy in patients with platinum-sensitive recurrent ovarian cancer deriving long-term benefit from maintenance niraparib: a subgroup analysis of the GEICO-88R studyJuan F Cueva, Isabel Palacio, Cristina Churruca, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Epigenetics|December 9, 2014
Methylation status of IGFBP-3 as a useful clinical tool for deciding on a concomitant radiotherapyOlga Pernía, Cristobal Belda-Iniesta, Veronica Pulido, et al.
British Journal of Cancer|October 26, 2022
Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib studyAlejo Rodriguez-Vida, Pablo Maroto, Albert Font, et al.
ESMO Open|August 20, 2019
A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancerJuan-Miguel Cejalvo, Wolfgang Jacob, Tania Fleitas Kanonnikoff, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 14, 2014
Assessment of ALK status by FISH on 1000 Spanish non-small cell lung cancer patientsJoana Vidal, Sergi Clavé, Silvia de Muga, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2017
First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid TumorsManuel Hidalgo, Maria Martinez-Garcia, Christophe Le Tourneau, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 28, 2022
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R StudyNicolas Girard, Jair Bar, Pilar Garrido, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 28, 2023
Open-label phase II clinical trial of ketoconazole as CYP17 inhibitor in metastatic or advanced non-resectable granulosa cell ovarian tumors: the GREKO (GRanulosa Et KetOconazole) trial, GETHI 2011-03Jesus Garcia-Donas, Alicia Hurtado, Laia Garrigos, et al.
Frontiers in Oncology|November 16, 2020
A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable <i>KRAS</i> Mutation Who Failed Prior Platinum-Based Therapy: JUNIPERJonathan W Goldman, Julien Mazieres, Fabrice Barlesi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2015
First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid TumorsDidier Meulendijks, Wolfgang Jacob, Maria Martinez-Garcia, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 20, 2025
Clinical outcomes and subsequent therapy in patients with platinum-sensitive recurrent ovarian cancer deriving long-term benefit from maintenance niraparib: a subgroup analysis of the GEICO-88R studyJuan F Cueva, Isabel Palacio, Cristina Churruca, et al.
Pageof 3